In a statement, U.S. Attorney’s Office said Balwani risked patient health by misrepresenting the accuracy of Theranos blood analysis technology and that defrauded Theranos investors of millions of dollars.
In a statement, U.S. Attorney’s Office said Balwani risked patient health by misrepresenting the accuracy of Theranos blood analysis technology and that defrauded Theranos investors of millions of dollars.